Sabiha Naim Qazi

Array ( [id] => 11196800 [patent_doc_number] => 09426994 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-30 [patent_title] => 'Synergistic microbicidal combinations' [patent_app_type] => utility [patent_app_number] => 14/714858 [patent_app_country] => US [patent_app_date] => 2015-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6532 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14714858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11255373 [patent_doc_number] => 09480258 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-01 [patent_title] => 'Synergistic microbicidal combinations' [patent_app_type] => utility [patent_app_number] => 14/714868 [patent_app_country] => US [patent_app_date] => 2015-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6532 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14714868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11961980 [patent_doc_number] => 20170266133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'METHODS AND COMPOSITIONS OF DASOTRALINE FOR TREATMENT OF ADHD' [patent_app_type] => utility [patent_app_number] => 15/310344 [patent_app_country] => US [patent_app_date] => 2015-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4261 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15310344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11962028 [patent_doc_number] => 20170266182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'Treatment of IgG-Immune Complex-Mediated Organ Damage' [patent_app_type] => utility [patent_app_number] => 15/309890 [patent_app_country] => US [patent_app_date] => 2015-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 9953 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15309890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11455908 [patent_doc_number] => 20170049815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'Selective Chemotherapy Treatments and Diagnostic Methods Related Thereto' [patent_app_type] => utility [patent_app_number] => 15/308493 [patent_app_country] => US [patent_app_date] => 2015-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7543 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15308493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340437 [patent_doc_number] => 20150225443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'NOVEL DERIVATIVES OF CHOLEST-4-EN-3-ONE OXIME, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PREPARATION METHOD' [patent_app_type] => utility [patent_app_number] => 14/696933 [patent_app_country] => US [patent_app_date] => 2015-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7731 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14696933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11469593 [patent_doc_number] => 20170056376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/306457 [patent_app_country] => US [patent_app_date] => 2015-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 20371 [patent_no_of_claims] => 78 [patent_no_of_ind_claims] => 39 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15306457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10331165 [patent_doc_number] => 20150216170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'Synergistic Microbicidal Combinations' [patent_app_type] => utility [patent_app_number] => 14/684791 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6532 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14684791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11099511 [patent_doc_number] => 20160296482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'ANTICANCER THERAPEUTIC AGENTS' [patent_app_type] => utility [patent_app_number] => 14/684259 [patent_app_country] => US [patent_app_date] => 2015-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7531 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14684259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419763 [patent_doc_number] => 20170027907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN' [patent_app_type] => utility [patent_app_number] => 15/300989 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20916 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15300989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10324360 [patent_doc_number] => 20150209364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'METHOD FOR TREATING EPIDERMOID CARCINOMA' [patent_app_type] => utility [patent_app_number] => 14/677271 [patent_app_country] => US [patent_app_date] => 2015-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6591 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14677271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700414 [patent_doc_number] => 20160046561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'SUBSTITUTED TETRACYCLINE COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 14/669238 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 48828 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14669238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11556152 [patent_doc_number] => 20170102398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'PREDICTING AND REDUCING COGNITIVE DECLINE BASED ON GSK-3 LEVELS' [patent_app_type] => utility [patent_app_number] => 15/122991 [patent_app_country] => US [patent_app_date] => 2015-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7555 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15122991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11497718 [patent_doc_number] => 20170071903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'USE OF ERIBULIN AND MTOR INHIBITORS AS COMBINATION THERAPY FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/123476 [patent_app_country] => US [patent_app_date] => 2015-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 12831 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15123476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10263555 [patent_doc_number] => 20150148552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => '23-YNE-VITAMIN D3 DERIVATIVE' [patent_app_type] => utility [patent_app_number] => 14/612781 [patent_app_country] => US [patent_app_date] => 2015-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14876 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14612781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11348830 [patent_doc_number] => 20160367571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'USE OF PARICALCITOL IN THE TREATMENT OF INFLAMMATORY ANAEMIA' [patent_app_type] => utility [patent_app_number] => 15/117896 [patent_app_country] => US [patent_app_date] => 2015-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 13403 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15117896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10987331 [patent_doc_number] => 20160184276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'Sphingosine kinase inhibition for the treatment and prevention of obstetrical disorders' [patent_app_type] => utility [patent_app_number] => 14/544357 [patent_app_country] => US [patent_app_date] => 2014-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3454 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14544357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13248931 [patent_doc_number] => 10137137 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-27 [patent_title] => ATP synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria [patent_app_type] => utility [patent_app_number] => 15/105761 [patent_app_country] => US [patent_app_date] => 2014-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 25112 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15105761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10220393 [patent_doc_number] => 20150105387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/570812 [patent_app_country] => US [patent_app_date] => 2014-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4528 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14570812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16642093 [patent_doc_number] => 10919929 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Glucocorticoid inhibitors for treatment of prostate cancer [patent_app_type] => utility [patent_app_number] => 15/103283 [patent_app_country] => US [patent_app_date] => 2014-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 72 [patent_no_of_words] => 40332 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15103283 [rel_patent_id] =>[rel_patent_doc_number] =>)